Shares of Aeglea Bio Therapeutics Inc (NASDAQ:AGLE) have earned an average rating of “Buy” from the six ratings firms that are currently covering the company, Marketbeat reports. Two research analysts have rated the stock with a hold rating and four have given a buy rating to the company. The average 12 month target price among brokers that have updated their coverage on the stock in the last year is $26.00.
Several research firms have recently commented on AGLE. Wells Fargo & Co cut shares of Aeglea Bio Therapeutics from an “outperform” rating to a “market perform” rating in a research note on Tuesday, September 4th. Zacks Investment Research cut shares of Aeglea Bio Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, July 11th.
In other news, insider Aaron Schuchart sold 6,000 shares of the stock in a transaction that occurred on Thursday, September 27th. The shares were sold at an average price of $9.50, for a total transaction of $57,000.00. Following the sale, the insider now directly owns 8,400 shares of the company’s stock, valued at $79,800. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 18.30% of the stock is owned by corporate insiders.
AGLE opened at $8.60 on Wednesday. Aeglea Bio Therapeutics has a one year low of $3.75 and a one year high of $12.00.
Aeglea Bio Therapeutics (NASDAQ:AGLE) last released its quarterly earnings results on Thursday, August 9th. The biotechnology company reported ($0.46) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.36) by ($0.10). Aeglea Bio Therapeutics had a negative net margin of 480.92% and a negative return on equity of 57.15%. The company had revenue of $2.38 million for the quarter. On average, research analysts expect that Aeglea Bio Therapeutics will post -1.8 earnings per share for the current year.
About Aeglea Bio Therapeutics
Aeglea BioTherapeutics, Inc, a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients with rare genetic diseases and cancer. The company's lead product candidate includes pegzilarginase, a recombinant human Arginase 1 enzyme, which is in early clinical development stage for the treatment of Arginase 1 deficiency, an autosomal recessive metabolic disease caused by a marked decrease in the activity of the native arginase 1 enzyme; and for treating Arginine dependent cancers.
Read More: What is the float in trading stocks?
Receive News & Ratings for Aeglea Bio Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aeglea Bio Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.